2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00573443 (ClinicalTrials.gov)	December 2007	13/12/2007	Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS	A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)	Pseudobulbar Affect (PBA)	Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: Placebo	Avanir Pharmaceuticals	INC Research	Completed	18 Years	80 Years	All	326	Phase 3	United States;Argentina;Brazil
2	NCT00021697 (ClinicalTrials.gov)	January 2001	1/8/2001	Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS	A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: AVP-923	Avanir Pharmaceuticals	NULL	Completed	18 Years	80 Years	Both	100	Phase 3	United States